Close Menu

NEW YORK – With the success of drugs like Merck's pembrolizumab (Keytruda) and Loxo Oncology and Bayer's larotrectinib (Vitrakvi), many companies that make oncology therapies are now trying their hand at developing histology-agnostic cancer drugs. But getting these treatments into patients' hands isn't simple — they must be tested in specifically designed clinical trials, approved by regulators, and paid for by insurance companies.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Mission Bio

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 


This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.